37th week of 2022 patent applcation highlights part 11 |
Patent application number | Title | Published |
20220288218 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE - Described herein is/are a therapeutic antisense oligonucleotide(s) which binds to exons 45 to 55 of the human dystrophin pre-mRNA to induce exon skipping, and conjugates and compositions thereof for the treatment of DMD. | 2022-09-15 |
20220288219 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF - Provided herein are antigen-binding protein constructs capable of specifically binding CD22 or an epitope of CD22 presented on the surface of a target mammalian cell, wherein said antigen binding is pH-dependent. Provided are also uses of said antigen-binding protein constructs. | 2022-09-15 |
20220288220 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele. | 2022-09-15 |
20220288221 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES - The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs. | 2022-09-15 |
20220288222 | USE OF IMMUNOCYTOKINE COMPRISING INTERFERON-BETA OR VARIANT THEREOF FOR TREATING HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE CANCER - The present invention relates to a use of a recombinant protein in which an interferon-beta protein and an antibody binding to a HER2 antigen are fused for the purpose of treating cancer patients of which the HER2 expression level is IHC 1+ or higher. The recombinant protein can exhibit efficacy better than conventional antibody therapeutic agents through cancer-specific anti-cancer immune responses in patients, thereby being used for more patients, and thus is effectively usable as a novel agent for treating cancer. | 2022-09-15 |
20220288223 | ACTIVATABLE SPECIFIC BINDING MEMBER COMPLEXES, AND METHODS OF MAKING AND USING SAME - Disclosed herein, the invention pertains to methods and compositions involving activatable specific binding member complex(es). | 2022-09-15 |
20220288224 | PHARMACEUTICAL AGENT FOR TRANSMUCOSAL ADMINISTRATION - Provided is a pharmaceutical agent for enhancing absorption efficiency of a drug through the mucosal epithelial layer. A pharmaceutical agent for transmucosal administration comprises as an active ingredient a drug compound to which a podocalyxin targeting molecule is bound. | 2022-09-15 |
20220288225 | MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES - Described herein are Natural Killer Group 2D (NKG2D) agonist complexes comprising a soluble MHC I Chain-related molecule (sMIC) and a non-blocking sMIC-neutralizing antibody. Methods for activating CD8 T cells and methods for treating MIC-negative cancers and viral infections using such complexes are also provided. | 2022-09-15 |
20220288226 | METHODS AND COMPOSITIONS TO TREAT AUTOIMMUNE DISEASES AND CANCER - Provided are molecular constructs that target tumor necrosis factor receptor 1 (TNFR1) and/or tumor necrosis factor receptor 2 (TNFR2). The constructs are for treating diseases, disorders, and conditions in which these receptors and/or TNF are involved in the etiology or in which their inhibition or activation thereof can ameliorate the disease, disorder, and condition or a symptom thereof. Among the constructs provided herein, are TNFR1 antagonist constructs that are engineered to inhibit TNFR1 function, and to eliminate any TNFR1 agonist activity. The constructs provided herein include agonists and antagonists of TNFR1 and TNFR2 Included also are agonists and antagonists of TNFR2. Agonists of TNFR2 increase regulatory T-cell function to control acute or chronic inflammation. Antagonists of TNFR2 decrease regulatory T-cell function thus increasing immunity, and are for treating cancer and certain immunodeficiency diseases. Methods of treatment of the various diseases in which TNF and its receptors play a role also are provided. Also provided are growth factor ligand trap constructs, and methods of use thereof for treatment of diseases, disorders, and conditions, including cancer. | 2022-09-15 |
20220288227 | Ultrasound Responsive Microbubbles And Related Methods - A microbubble composition, comprising: a plurality of microbubbles, a microbubble comprising a noble gas and/or perfluorocarbon encapsulated within a shell that comprises one or more of a lipid, a protein, or a polymer, and a microbubble optionally defining a cross-sectional dimension in the range of from about 0.5 to about 20 micrometers. A method, comprising forming a composition according to the present disclosure. A method, comprising administering a microbubble composition according to the present disclosure to a subject, the composition optionally comprising echogenic phospholipid microbubbles. A method, comprising: (a) identifying, with the application of energy, the location of a microbubble composition according to the present disclosure, the energy optionally being ultrasound, (b) controllably effecting rupture of microbubbles of a microbubble composition of the present disclosure, the rupture optionally being effected by application of ultrasound, or both (a) and (b). | 2022-09-15 |
20220288228 | METHODS OF CANCER TREATMENT BY DELIVERY OF siRNAs AGAINST BCLXL AND MCL1 USING A POLYPEPTIDE NANOPARTICLE - Compositions and methods are provided for the silencing of the BCLxL and MCL1 genes. Specifically, siRNA compositions are provided that contain siRNA molecules that target the BCLxL and MCL1 genes. Methods for using these compositions for treating cancer also are provided. | 2022-09-15 |
20220288229 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF - Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases. | 2022-09-15 |
20220288230 | RNA-BASED THERAPEUTIC METHODS TO PROTECT ANIMALS AGAINST PATHOGENIC BACTERIA AND / OR PROMOTE BENEFICIAL EFFECTS OF SYMBIOTIC AND COMMENSAL BACTERIA - The invention relates to a method to inhibit gene expression in bacteria, which is referred to here as Antibacterial Gene Silencing (AGS). In particular embodiments, the method is used to protect plants and animals against pathogenic bacteria by targeting pathogenicity factors and/or essential genes in a sequence-specific manner via small non-coding RNAs. The method can also be used to enhance beneficial effects and/or growth of symbiotic or commensal bacteria. The invention involves the exogenous delivery of small RNA entities onto bacteria, either in the form of RNA extracts or embedded into plant extracellular vesicles (EVs), so as to reduce bacterial growth, survival and/or pathogenicity. The invention also describes a method to identify in a rapid, reliable and cost-effective manner, small RNAs that possess antibacterial activity and that have the potential to be further developed as anti-infective agents. In addition, the latter method is instrumental to rapidly characterize any gene from any bacterial species. | 2022-09-15 |
20220288231 | METHODS AND COMPOSITIONS FOR REDUCING GENE OR NUCLEIC ACID THERAPY-RELATED IMMUNE RESPONSES - This disclosure provides methods and pharmaceutical compositions for attenuating immune response in a subject suffering from a genetic disorder and receiving gene or nucleic acid therapy. The pharmaceutical compositions and formulations may include immunosuppressants, such as protein kinase inhibitors, including tyrosine kinase inhibitors (TKIs), in conjunction with various types of therapeutic nucleic acids (TNAs) and carriers (e.g., lipid nanoparticles). | 2022-09-15 |
20220288232 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING MACULAR DEGENERATION - Compositions and methods for treating macular degeneration are disclosed. The methods utilize gene delivery to human eyes of soluble Flt-1 receptors, as well fusion proteins including a soluble Flt-1 receptor. | 2022-09-15 |
20220288233 | GENE THERAPY FOR TREATING HEMOPHILIA B - Compositions and regimens useful in treating hemophilia B are provided. The method involves administering to the human subject via a peripheral vein by infusion of a suspension of replication deficient recombinant adeno-associated virus (rAAV). | 2022-09-15 |
20220288234 | MODIFIED ADENO-ASSOCIATED VIRUS (AAV) PARTICLES FOR GENE THERAPY - The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for producing the improved AAV particles of this invention by removing natural binding sites in adeno associated virus (AAV) capsids and introducing ligand binding sites into said capsid to provide AAVs that transduce only particular cells of interest. An additional aspect of the present invention relates to modified AAV particles for use in the treatment of a disease and methods for treating a disease, comprising administering the modified AAV particles to a subject in need thereof. Yet a further aspect of this invention relates to the AAV particles of this invention for the transfection of cells, for example as a gene delivery tool in basic research. | 2022-09-15 |
20220288235 | SCHIZOPHRENIA-RELATED MICRODELETION GENE 2510002D24Rik IS ESSENTIAL FOR SOCIAL MEMORY - Described is a method for treating a social memory deficit in a subject with a neuropsychiatric disease is treated by administering a peptide encoded by 2510002D24Rik or Atp23 genes, a vector expressing such peptide, or an agent capable of increasing the level or activity of such peptide. The method may be used to treat schizophrenia or autism. The peptide, vector or agent can be administered directly to the hippocampus, such as by transcranial surgical injection. | 2022-09-15 |
20220288236 | COCHLEAR OUTER HAIR CELL PROMOTERS AND USES THEREOF - The disclosure provides polynucleotides containing outer hair cell-specific promoters, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in outer hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote outer hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss. | 2022-09-15 |
20220288237 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION - The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of an apolipoprotein B (APOB) gene by targeting an APOB expression control region and methods of use thereof for treating an APOB associated disorder, e.g., hypercholesterolemia. | 2022-09-15 |
20220288238 | COMPOSITIONS FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION - A recombinant adeno-associated virus (rAAV) having an AAV8 capsid which is suitable for intra-retinal injection is provided herein. The rAAV comprises a vector genome packaged within the capsid which contains, operably linked to regulatory elements which direct expression of anti-human vascular endothelial growth factor (VEGF) antigen binding antibody fragment (aVEGF), a coding sequence for aVEGF, wherein the coding sequence is operably linked to regulatory elements which direct expression of the anti-VEGF Fab in the eye. Also provided herein are liquid suspensions containing these rAAV8.aVEGF and methods of using same for treatment of wet AMD and other ocular conditions. | 2022-09-15 |
20220288239 | RABIES VACCINE - The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. | 2022-09-15 |
20220288240 | Use of Thermostable RNA Polymerases to Produce RNAs Having Reduced Immunogenicity - Provided herein, among other things, is a method for producing an RNA product that has reduced immunogenicity. In some embodiments, the method involves transcribing a template DNA with a thermostable RNA polymerase at a temperature of greater than 44° C. | 2022-09-15 |
20220288241 | LARGE SCALE PRODUCTION OF EXOSOME MIMETICS AND USES THEREOF - Provided herein are methods of producing exosome mimetics that are homogenous in size and are akin to native exosomes in structure and/or biological function. Also provided herein are the use of the EMs as delivery vehicles to deliver agents (e.g., therapeutic agents or diagnostic agents) for treating or diagnosing a disease. | 2022-09-15 |
20220288242 | METHOD OF PREPARING A RADIOACTIVE YTTRIUM PHOSPHATE PARTICLE SUSPENSION - A method of preparing a radioactive yttrium salt particle suspension comprising multiple steps comprising: using a hydrothermal process wherein a solution of soluble yttrium salt, from the group of yttrium chloride, yttrium nitrate, yttrium sulfate, and yttrium bromide is combined with a solution of sodium phosphate having a stoichiometric excess of phosphate and a preferred pH when combined. | 2022-09-15 |
20220288243 | LIGANDS FOR IMAGING CARDIAC INNERVATION - Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable. | 2022-09-15 |
20220288244 | COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER - Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRPα-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRPα. | 2022-09-15 |
20220288245 | RADIOPHARMACEUTICAL COMPOUND AND COMPOSITION FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF INTERLEUKIN-2 RECEPTOR POSITIVE CELLS, PROCESS FOR THE PREPARATION THEREOF, RELATED KIT AND USES THEREOF - The present invention relates to a radiopharmaceutical compound or composition for Positron Emission Tomography (PET) imaging of interleukin-2 (IL2) receptor positive cells, in particular, | 2022-09-15 |
20220288246 | ADDITIONAL MASS TAG POLYMERS FOR MASS CYTOMETRY - A new class of mass-tag polymers is provided, which include enriched metal isotopes such as zirconium and hafnium mass tags. The chemistry of these new mass tags are different from that of lanthanide mass tags, and opens up new mass channels that can be used in mass cytometry. These polymers may be used for mass cytometry, therapeutic delivery of a radioactive isotope, or screening of a therapeutic isotope. Aspects include a kit, method of making, and method of using a polymer, isotopic composition, or both. A kit may include a polymer. The polymer may include pendant groups that chelate an enriched isotope, such as zirconium and/or hafnium. The kit may include an isotopic composition comprising an enriched zirconium or hafnium isotope. Polymers may be conjugated to a biologically active material. Aspects may also include making a kit. Aspects include use of a kit, such as for mass cytometry. | 2022-09-15 |
20220288247 | DRY STERILIZING DEVICE AND DRY STERILIZING METHOD - A sterilizing device includes a housing having an opening in at least one direction thereof. The housing also has a hollow portion configured to allow insertion of an object (target) including part of a human body from the opening into the hollow portion. The sterilizing device also includes at least one air blower unit configured to send a flow of air toward an interior of the hollow portion, and at least one ultraviolet light emitting unit configured to emit ultraviolet light toward the interior of the hollow portion. The ultraviolet light emitted from each ultraviolet light emitting unit includes at least part of ultraviolet light having a wavelength between 190 nm and 230 nm and at least part of ultraviolet light having a wavelength between 230 nm and 237 nm, but does not include ultraviolet light having a wavelength below 190 nm and beyond 237 nm. | 2022-09-15 |
20220288248 | CONNECTION SYSTEM AND ACTIVE STERILIZER FOR A DRUG DELIVERY DEVICE - A method and system for creating an aseptic connection is disclosed. The method includes arranging a heating element between a first outer sealing surface and a second outer sealing surface such that the heating element is in contact with the first outer sealing surface and the second outer sealing surface. The method further includes applying opposing forces to the first and second outer sealing surfaces such that the first and second outer sealing surfaces are biased towards each other and heating the heating element to sterilize the first outer sealing surface and second outer sealing surface. The method also includes removing the heating element from between the first seal and second seal while continuing to apply the opposing forces to the first and second outer sealing surfaces such that the aseptic connection is simultaneously formed between the first and second outer sealing surfaces. | 2022-09-15 |
20220288249 | METHOD OF SELF-DISINFECTION OF MOBILE ROBOT - Implementations of the disclosed subject matter provide a method that includes moving a mobile robot in a path within a predetermined area using a drive system of the mobile robot, and outputting ultraviolet (UV) light from a first light source onto a portion of at least one of a plurality of wheels of the drive system based on a first dosage level. | 2022-09-15 |
20220288250 | CONTROL DEVICE, IN-VEHICLE STERILIZATION SYSTEM, CONTROL METHOD, AND CONTROL PROGRAM - A control device that controls an ultraviolet emission device such that the inside of a vehicle is sterilized is provided. The control device includes a vehicle state acquiring unit configured to acquire a state of the vehicle, a determination unit configured to determine whether a person is present inside of the vehicle based on the state of the vehicle, and a control unit configured to control the ultraviolet emission device with reference to a result of determination of whether a person is present inside of the vehicle. | 2022-09-15 |
20220288251 | HANDHELD GERMICIDAL LIGHT TOOL WITH DISTANCE AND POWER FEEDBACK - A handheld disinfection tool utilizing UVC light may feature a UVC light source ( | 2022-09-15 |
20220288252 | WORK SPACE DISENFECTION APPARATUS AND METHOD - Disinfection devices positionable to disinfect work spaces within an office of an office building or other work area can be configured or incorporated into a lighting device, ceiling mounted device, baffle, furniture, or other type of disinfection device. Embodiments can be configured to utilize UVC-222 light or other UVC light to disinfect the work area. In some embodiments, the disinfecting light can be applied at a pre-selected time of night when the work area is expected to have no staff or limited numbers of staff therein. The distribution of the disinfection light can be configured to help ensure application of the light for a pre-selected time period applies at least a pre-selected dose of the light to the work area for sufficient, if not complete, disinfection of objects within the work area that include papers, furniture, and other items. | 2022-09-15 |
20220288253 | VIRUCIDAL EFFECTS OF 405 NM VISIBLE LIGHT ON SARS-COV2 AND INFLUENZA A VIRUS - A lighting device and methods thereof to inactivate viruses in an environment. Particularly, systems and methods demonstrate the virucidal effects of 405 nm irradiation to inactivate viruses including SARS-CoV-2 and influenza A H1N1 virus, specifically in the absence of exogenous photosensitizers, despite previous efforts in the field suggesting the need for one or more photosensitizers to achieve successful inactivating effect. Moreover, systems and methods implement the 405 nm in the context of lighting devices that may disinfect an environment while providing a combined light output that is unobjectionable to humans. | 2022-09-15 |
20220288254 | SMART, RAPID, SAFE DISINFECTION METHODS, DEVICES, AND SYSTEMS FOR FLUSHOMETERS, TOILETS, FAUCETS, BATHS, AND SHOWERS - A light-based sterilization source directs a blue light at a touched or contacted surface for eliminating harmful viral or bacterial contaminants. The blue light is outside the range of harmful UV light while delivering an effective decontaminating light source for eradication of pathogenic microorganisms. An irradiation device includes a light source disposed for irradiating a bathroom or fixture surface for sterilization. A corresponding system for sterilization of contaminated surfaces using the irradiation device includes a blue light source having a wavelength outside a harmful spectrum such as the UV (ultraviolet) spectrum. | 2022-09-15 |
20220288255 | METHOD FOR DECONTAMINATING A PREFORM WITH REACTIVE SPECIES OBTAINED BY MIXING A PRECURSOR AGENT AND A PLASMA - The invention relates to a method for decontaminating a preform made of thermoplastic material by exposing at least part of the preform to reactive species obtained by mixing a precursor agent with a plasma, the plasma being generated by injection of a carrier gas into a reactor, the method including mixing of the precursor agent with the plasma is carried out exclusively outside the reactor before it is in contact with the preform. The invention also relates to a decontamination device for carrying out the method. | 2022-09-15 |
20220288256 | STERILIZATION WASHING METHOD AND STERILIZATION WASHING DEVICE - The present invention provides a method of disinfection and cleaning capable of, in conjunction with removing, by washing, dust and grit, dirt, and the like adhered to an underside of an object to be disinfected and cleaned such as traveling bags or suitcases, space disinfection as well as a disinfection and cleaning apparatus. The method of disinfection and cleaning includes a step of removing dust and grit and bacteria and the like adhered to the underside of the object to be disinfected and cleaned by contact with a disinfecting and cleaning fluid by means of cleaning and removal means. A disinfection and cleaning apparatus | 2022-09-15 |
20220288257 | COMPOSITIONS AND METHODS FOR DECONTAMINATION OF SURFACES - Disclosed are methods and compounds useful for forming coatings applied to porous and non-porous surfaces to make the surface antimicrobial and to protect against contaminants. The coatings are formed from phenolic compounds present in a solvent either alone or in combination with other compounds, such as metallic salts. | 2022-09-15 |
20220288258 | CAPS TO PROVIDE A PHYSICAL BARRIER TO AN ACCESS SITE OF A MEDICAL CONNECTOR - Caps and packaging for use with a medical device (e.g., connector, luer access device, etc.) are disclosed herein. The caps can be applied to a surface of a medical device and can comprise a cap body having a bottom wall and a sidewall extending therefrom, the sidewall defining a top opening, a fluid contained within the cap body, and a deformable top wall connected to the cap body, the top wall movable from a first position sealing the fluid within the cap body to a second position releasing the fluid from the cap body. | 2022-09-15 |
20220288259 | ATOMIC OXYGEN AND OZONE CLEANING DEVICE HAVING A TEMPERATURE CONTROL APPARATUS - Embodiments of the present disclosure relate to an oxygen cleaning chamber with UV radiation generator temperature control and a method of atomic oxygen cleaning a substrate. The atomic oxygen cleaning chamber includes a process chamber and a cooling chamber coupled to the process chamber and a divider sealingly separating the process chamber from the cooling chamber. An ultraviolet (UV) radiation generator is disposed in the cooling chamber and provides UV radiation through the divider into the process chamber. A gas distribution assembly distributes ozone over an upper surface of a pedestal in the process chamber and a coolant distribution assembly distributes cooling gas into the cooling chamber to cool the UV radiation generator. By actively cooling the UV radiation generator, a higher intensity UV radiation at a stable wavelength is produced, i.e., without wavelength drift normally associated with high power UV radiation generator outputs. | 2022-09-15 |
20220288260 | Grain Treatment Apparatus Using Ozone - An ozone treatment apparatus for grain uses first and second storage bins and an auger conveyor for conveying the grain from a first end in communication with the bottom of the first bin to a second end that can be directed into either one of the top of the first bin or the top of the second bin. An ozone injector injects ozone into the auger conveyor for mixing with and treating the conveyed grain. In a first mode, the conveyor discharges the grain from the second end of the conveyor through a first discharge outlet into the first storage bin to recycle the grain during treatment. In a second mode, the conveyor discharges the grain through a second discharge outlet into the second storage bin once treatment is complete. | 2022-09-15 |
20220288261 | PREDICTING SPHERICAL IRRADIANCE FOR VOLUME DISINFECTION - Given the complexity of architectural spaces and the need to calculate spherical irradiances, it is difficult to determine how much ultraviolet radiation is necessary to adequately kill airborne pathogens. An interior environment with luminaires is modeled. Spherical irradiance meters are positioned in the model and the direct and indirect spherical irradiance is calculated for each sensor. From this, an irradiance field is interpolated for a volume of interest, and using known fluence response values for killing pathogens, a reduction in the pathogens is predicted. Based on the predicted reduction, spaces are built accordingly, and ultraviolet luminaires are installed and controlled. | 2022-09-15 |
20220288262 | ORAL DEVICE CONTAINER AND ORAL DEVICE SANITATION SYSTEM - An oral sanitation system may include a case including: a support portion defining a lower end of the case; and a container portion extending from the support portion. The container portion may define a wall extending from the support portion to a top end of the container portion. The oral sanitation system may further include a closure including a lid formed with a peripherally-extending wall; a lower cavity defined by the wall of the container portion; an upper cavity defined by the peripherally-extending wall of the closure; and a light-guiding floor that is substantially transparent to UVC light, the light-guiding floor forming a bottom of the container portion that is surrounded by the wall. | 2022-09-15 |
20220288263 | AROMATIC DEODORIZING DEVICE - An aromatic deodorizing device generates a deodorant component that removes a target malodor. The aromatic deodorizing device includes a sensor that detects an index indicating an odor strength of the target malodor, a plurality of different aromatic deodorants, and a switching unit that changes the aromatic deodorant that is to be a source of the deodorant component in accordance with a detection value of the sensor. | 2022-09-15 |
20220288264 | FRAGRANCE DIFFUSION DEVICE AND FRAGRANCE DIFFUSION METHOD - [Technical Problem] The problem of the present invention is to provide a fragrance diffuser which can diffuse a fragrance efficiently from a fragrance source with a calm atmosphere. | 2022-09-15 |
20220288265 | SYSTEMS AND METHODS FOR DIFFUSING ESSENTIAL OILS - Some implementations of the present invention relate to systems and methods for diffusing scents to a given location by placing a scent reservoir within a vessel including an inner chamber, a vent, and a selectively closable opening. In some cases, the scent reservoir is secured within the vessel while allowing the desired aroma to diffuse into the surrounding area through the vent. In some cases, the inner chamber comprises a wall or layer that is less permeable to the scent than is the vent. Accordingly, in some cases, the inner chamber is configured to direct the scent from the scent reservoir to the vent, which is disposed at an outer surface of the vessel. While the vessel can be any suitable object, in some cases, it is a stuffed animal. Other implementations are also described. | 2022-09-15 |
20220288266 | MASK WITH ULTRAVIOLET DISINFECTION OF INHALED AND EXHALED AIR - The mask with ultraviolet disinfection of inhaled and exhaled air in the form of a filtering-purification protective front surface contains a removable unit, the inner surface of which is covered with an ultraviolet radiation source with a pluggable independent power supply system. The filtering-purification unit has rows of meshes composed of light guides of ultraviolet radiation spectrum with tapped radiation in each cell of the mesh, and a source is brought to the meshes. The mask itself can be made of a mesh composed of light guides. The mask in the form of a shield in front of the face is represented by a mesh composed of light guides in front of the face or along the entire perimeter. The mask along the bottom part of the headband, above the face, is provided with a LED strip of ultraviolet radiation spectrum, radiation being directed downward, the sector of directed radiation being adjustable. The headgear can serve as a headband. Also, the LED radiation strip is attached to the eyeglasses along the perimeter of the spectacle frame. | 2022-09-15 |
20220288267 | REPLACEABLE UV LAMP CARTRIDGE FOR AIR PURIFICATION SYSTEMS - A an example replaceable ultraviolet (UV) lamp cartridge includes: a tamper-proof UV energy absorbing shell containing one or more UV radiation emitting devices; an air inlet disposed at a first end of the tamper-proof UV energy absorbing shell; an air outlet disposed at a second end of the tamper-proof UV energy absorbing shell; and a self-aligning connector for receiving external voltage to be supplied to the UV energy emitting devices. | 2022-09-15 |
20220288268 | METHOD, APPARATUS AND SYSTEM FOR REDUCING PATHOGENS IN A BREATHABLE AIRSTREAM IN AN ENVIRONMENT - An air flow system for reducing pathogens in a breathable airstream in an environment has a device having an airstream intake for receiving a volume of untreated air located in a first position, an airstream outlet for expelling a volume of treated air, the airstream outlet located in a second position extending above the first position, a flow path extending between the airstream intake and the airstream outlet, at least one of a UV generator and a UV-C emitter optically coupled to the flow path, a power source operably connected to the one of the at least one of the UV generator and the UV emitter, and a pressure generator fluidly connected to the airstream intake, the pressure generator configured to impart a flow from the airstream intake to the airstream outlet, wherein the pressure generator can be at least one of a force of flow from in line pressurized source or provided by a fan within the housing, and wherein a portion of the flow path includes a UV-C highly reflective surface. | 2022-09-15 |
20220288269 | OCULAR DEVICE CASE AND REFILL CONTAINER USED FOR THE OCULAR DEVICE CASE - An ocular device case with a new structure that can solve unexpected problems in the related art, for example, adverse effects on user's eyes by splashes of treatment liquid upon pouring the treatment liquid into the device case from a separate refill container. In a device case including: a case body accommodating treatment liquid with ocular devices such as a contact lens; and a lid, a container receiving portion is provided such that a spout of a refill container is brought into contact with the refill receiving portion so as to allow the treatment liquid to flow into the device case. | 2022-09-15 |
20220288270 | PACKAGING SOLUTIONS - A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes one or more conjugated glycosaminoglycans having a polymer backbone having a reactive functional moiety conjugated to an amine group having one or more moieties that inhibit and/or prevent one or more of oxidation and hydrolytic degradation of the polymer backbone during use in the eye; wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized. | 2022-09-15 |
20220288271 | BIOADHESIVE COMPOSITION COMPRISING MUSSEL ADHESIVE PROTEIN AND PREPARATION METHOD THEREOF - The present disclosure relates to a bioadhesive composition including mussel adhesive protein; and at least one of polyacrylic acid and polymethacrylic acid; in which the mussel adhesive protein is linked to the at least one of polyacrylic acid and polymethacrylic acid by an amide bond and has a three-dimensional network structure and a method for preparing the same. | 2022-09-15 |
20220288272 | IMPLANT COMPRISING A PLURALITY OF HARDENING STATES - The present invention relates to a deformable body formed of at least 20% by volume of a polymer material in which individual polymer backbones have a plurality of functional groups capable of cross-linking to form a cross-link; said polymer material provided in a first less-cross- linked configuration; wherein said polymer material, upon application of a suitable stimuli, said stimuli causes cross-linking of said functional groups to form cross-linking between said polymer backbones such that said polymer material is in a second more-crosslinked configuration. | 2022-09-15 |
20220288273 | OSTEOINDUCTIVE MODIFIED GELATIN HYDROGELS AND METHODS OF MAKING AND USING THE SAME - The present invention relates in part to a hydrogel composition and a method of fabricating the hydrogel composition comprising the steps of providing a solution comprising a polymer comprising crosslinkable groups; providing a solution comprising a crosslinking agent; mixing the solution comprising a polymer comprising crosslinkable groups and the solution comprising the crosslinking agent to form a combined solution; and crosslinking the combined solution. The invention also relates in part to a methods of treatment using the hydrogel composition. | 2022-09-15 |
20220288274 | BIOENERGETIC BONE - A biological composition has a mixture of mechanically selected allogeneic biologic material derived from bone marrow. The mixture has non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components. The mixture including non-whole cell fractions including one or more of exosomes, transcriptosomes, proteasomes, membrane rafts, lipid rafts. The mixture is compatible with biologic function. | 2022-09-15 |
20220288275 | SYSTEM AND METHOD FOR HARVESTING AUTOLOGOUS ADIPOSE TISSUE - A triple-chambered container includes: a main container body with a first chamber which has an opening at its distal end; a main barrel formed and movable longitudinally within the first chamber, the main barrel defining therein a second chamber for receiving fluids, the main barrel further having an apertured stopper at its distal end; a second barrel formed within the main barrel, the second barrel defining a third chamber for receiving fluids, the second barrel being movable longitudinally within and with respect to the main barrel, the second barrel having a distal end which is engageable and disengageable with the apertured stopper; a shaft adapted to fit within the second barrel, the shaft being movable longitudinally within and with respect to the second barrel, the shaft having a distal end which is engageable and disengageable with an aperture in the second barrel; a device for controlling engaging and disengaging of the distal end of the shaft with the aperture of the second barrel. The first chamber, the second chamber and the third chamber may be selectively moved to receive and discharge fluids with respect to one another. | 2022-09-15 |
20220288276 | ARTIFICIAL ENDOTHELIAL KERATOPLASTY GRAFT AND METHODS OF PREPARATION THEREOF - The present invention discloses an artificial endothelial keratoplasty graft consisting a support layer made of rehydrated crosslinked hydrogel and corneal endothelial cells on top or within said support layer. The invention also discloses a method of manufacturing an artificial endothelial keratoplasty graft, wherein said method consisting of a step of drying support layer material followed by a crosslinking step. | 2022-09-15 |
20220288277 | SURFACE COATINGS AND IMPLANTABLE DEVICES COMPRISING DIMERIC STEROID PRODRUGS, AND USES THEREOF - The disclosure features surface coatings formed from dimeric steroid prodrugs for the extended delivery of a drug from a surface, and for the treatment of a disease or condition. Also provided herein are drug depots formed from dimeric steroid prodrugs for the extended delivery of a drug for use in combination with implantable medical devices. Said dimeric steroid prodrugs are represented by the formula D1-L-D2, wherein D1 and D2 are independently a steroid radical and L is a linker covalently linking D1 to D2. | 2022-09-15 |
20220288278 | ULTRASOUND MEDIATED POLYMERIZATION FOR CELL DELIVERY, DRUG DELIVERY AND 3D PRINTING - An aspect of the invention relates to methods and implants comprising acoustic-sensitive material and at least one additional component within said acoustic-sensitive material. In some embodiments, the at least one additional component is one or more of at least one releasable drug within said acoustic-sensitive material and/or a plurality of cells within said acoustic-sensitive material. In some embodiments, the implant comprises a dedicated form, which is provided inside the body of the patient. | 2022-09-15 |
20220288279 | ZWITTERIONIC HYDROGELS FOR DELIVERY OF BIOMOLECULES - The invention provides a novel approach in which zwitterionic networks are used to sequester and deliver ionic biomolecules, such as proteins, without compromising their native conformation and bioactivity. Zwitterionic networks are designed to effectively retain and deliver ionic or polar biomolecules for guided tissue regeneration. The invention represents a conceptual advance and enables a novel strategy for the utilization of zwitterionic motifs as therapeutics delivery vehicles and tissue engineering scaffolds. | 2022-09-15 |
20220288280 | ANTIMICROBIAL COATING COMPOSITION AND ANTIMICROBIAL COATING METHOD USING SAME - Disclosed is an antimicrobial composition and a coating method using the same. The composition is highly hydrophilic and biocompatible, thereby enabling a thin and flexible coating layer and exhibiting antimicrobial activity. The coating composition of the present invention is suitably used for coating vascular catheters, stents, guide wires, and other invasive medical devices. | 2022-09-15 |
20220288281 | BORON CARBON NITRIDE (BCN) NANOCOATINGS ON CENTRAL VENOUS CATHETERS INHIBIT BACTERIAL COLONIZATION - A novel anti-microbial coating and uses thereof on medical devices are presented. The novel coating is comprised of a layer of boron carbon nitride (BCN) coated onto a medical device such as a catheter. The BCN coating was found to inhibit bacterial growth by at least 80% and reduce biofilm formation by at least 60% on the treated surface of the catheter. This coating can be used to reduce or prevent central line associated bloodstream infections (CLABSI) in patients as well as inhibit bacterial growth and biofilm formation on a variety of medical devices or polymeric surfaces. | 2022-09-15 |
20220288282 | INTERMITTENT CATHETERS - The invention relates to intermittent catheters comprising a calixarene bonded to a surface thereof, in particular to provide a bacteria-repellent and/or lubricous coating on the outer surface of an intermittent catheter. The calixarene moiety may comprises hydrophilic surface groups to provide lubricity, whilst also providing a bacteria-repellent effect, especially useful preventing discomfort and/or infection for a user inserting multiple catheters per day. | 2022-09-15 |
20220288283 | POLYMER FILM AND POLYMERIC BAG FOR HOLDING A MEDICAL-TECHNICAL PRODUCT TO BE IMPLANTED - The polymer film serves for the embedding of a medical technology product to be implanted in a human organism. The polymer film includes a polymer of natural origin being biodegradable and absorbable by the human body. The polymer film has a polymer content. The polymer film further includes two antimicrobial active ingredients having a different mechanism of action and the polymer film has a total active-ingredient content. The ratio of the total active-ingredient content to the polymer content is at least 15%. The polymer content is greater than the total active-ingredient content. The polymer film is bendable and modulable and uninterrupted. The polymer forms a polymer matrix in which the antimicrobial active ingredients are embedded in a homogeneously distributed manner. The polymer film has, for each of the antimicrobial active ingredients, an individual active-ingredient content deviating from one another by at most 20%. | 2022-09-15 |
20220288284 | MEDICAL DEVICES FOR CONTINUOUS DELIVERY OF THERAPEUTIC AGENTS - The present invention relates to compositions and methods to provide continuous and controlled release of therapeutic agent(s) during a procedure such as an interventional vascular procedure, e.g., to reduce acute and chronic complications and improve outcomes. | 2022-09-15 |
20220288285 | CATIONIC NANODRUG, PREPARATION METHOD THEREFOR, AND DRUG-LOADED IMPLANTABLE MEDICAL DEVICE - Disclosed are a cationic nanodrug, a preparation method therefor, and a drug-loaded implantable medical device, wherein the cationic nanodrug comprises a vector and a drug loaded on the vector, and the vector comprises one or more of a cationic amphipathic compound and a cationic modifier; the cationic amphipathic compound is a cationic amphipathic compound containing amino and/or acyl; and the cationic modifier is a cationic modifier containing amino and/or acyl. The cationic nanodrug greatly improves the uptake of a drug by cells and has a good slow-release effect. | 2022-09-15 |
20220288286 | ANTITHROMBOTIC COATING COMPOSITION AND ANTITHROMBOTIC COATING METHOD USING SAME - Disclosed is an antithrombotic coating composition and a coating method using the same. The composition is highly hydrophilic and biocompatible, thereby enabling a thin and flexible coating layer. The composition is suitably used for coating vascular catheters, stents, guide wires, and other invasive medical devices. | 2022-09-15 |
20220288287 | SYSTEM AND METHOD FOR CASSETTE IDENTIFICATION AND LOCKOUT - The present invention is generally directed to improved methods, devices, and systems for controlling the use of surgical cassette in a surgical system, comprising a console, a handpiece in communication with the console, a cassette receptacle configured to couple a cassette to the console having a pre-load detection system, and a cassette having a body portion configured to contact the pre-load detection system, wherein an indication from the pre-load detection system identifies the cassette, and wherein the system adjusts one or more settings based on the identified cassette. | 2022-09-15 |
20220288288 | BAG SYSTEM FOR COLLECTING BLOOD FROM ANIMALS - Bag system ( | 2022-09-15 |
20220288289 | SMART MILK LETDOWN EXPRESSION SYSTEM - A system includes a breast shield configured to mount to a breast during a breast milk letdown process. The breast shield includes one or more sensors integrally mounted thereon. The system also includes an analyzer configured to collect and analyze data obtained by the one or more sensors to extract information reflecting a condition of the breast. | 2022-09-15 |
20220288290 | Medical Fluid Cassette Leak Detection Methods And Devices - This disclosure relates to medical fluid cassette leak detection methods and devices. In some implementations, a method of detecting micro-leaks in a medical fluid cassette, the method includes decreasing a pressure between a vacuum reservoir of a medical treatment machine and a membrane of the medical fluid cassette when the medical fluid cassette is coupled to the medical treatment machine; measuring, using a flow meter, a rate of net fluid flow between the vacuum reservoir and the membrane of the medical fluid cassette; determining that the rate of net fluid flow between the vacuum reservoir and the membrane of the medical fluid cassette is above a threshold value; and in response to determining that the rate of net fluid flow is above the threshold value, causing the medical treatment machine to take a particular action. | 2022-09-15 |
20220288291 | DEVICE AND METHOD FOR EXTRACORPOREAL BLOOD TREATMENT AND METHOD FOR THE BALANCE CONTROL OF A DIALYSIS LIQUID IN AN EXTRACORPOREAL BLOOD TREATMENT - A device and method for extracorporeal blood treatment, in particular for hemodialysis, and a method for the balance control of a dialysis fluid in an extracorporeal blood treatment. Sodium balancing can be implemented with improved accuracy during the blood treatment, because distorting effects in the conductivity measurement of the used dialysis fluid can be corrected by taking into account the loading of the used dialysis fluid with urophanic substances, which loading is sensed by an additional measuring apparatus. | 2022-09-15 |
20220288292 | SOLUTIONS FOR CONTINUOUS INFUSION OF A DRUG ADMINISTERED VIA DIALYSIS AND DOSING ALGORITHM THEREFOR - A method of preparing a solution for use during a dialysis, hemodialysis, or Continuous Renal Replacement Therapy (CRRT) treatment of a patient is provided. An antibiotic or other drug is added ( | 2022-09-15 |
20220288293 | METHOD FOR PRIMING AN EXTRACORPOREAL BLOOD CIRCUIT OF AN APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD AND APPARATUS FOR EXTRACORPOREAL TREATMENT OF BLOOD - A method for priming an extracorporeal blood circuit of an apparatus for extracorporeal treatment of blood comprises: feeding a priming fluid in the extracorporeal blood circuit and into a blood side of a membrane gas exchanger ( | 2022-09-15 |
20220288294 | SYSTEM AND METHOD FOR REMOVAL OF IMMUNE INHIBITORS FROM BIOLOGICAL FLUIDS - The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity. | 2022-09-15 |
20220288295 | Nasal aspirator suction bin assembly - A nasal aspirator suction bin assembly comprises a suction bin base, which has a first connecting end connected with a host and a second connecting end connected with a suction bin cover; after the suction bin base is connected with the suction bin cover, a cavity is formed therein; the middle of the suction bin base is provided with an outlet tube, which runs through the suction bin base and extends into the cavity; the upper end of the suction bin cover is provided with a suction tube, which runs through the suction bin cover and extends into the cavity; a bracket is arranged in the cavity, and the bracket comprises a bracket tube which can be inserted on the outlet tube and a baffle arranged at the other free end of the bracket tube, and at least one air hole is arranged on the bracket tube to keep the suction tube and the outlet tube in communication all the time; the cavity is used to store the inhaled nasal fluid. Because of the umbrella-shaped bracket, the nasal fluid cannot touch the position of the air hole during normal use and small-angle inclined use, so the nasal fluid cannot enter the host and cause pollution. | 2022-09-15 |
20220288296 | System And Method To Clear Conduits Of Fluids After Instillation To A Wound - A wound therapy system and method for clearing fluids from a conduit includes a wound dressing apparatus, a pneumatic pump, a valve, and a controller. The wound dressing apparatus is fluidly coupled to a wound, the pump, and the valve. The controller is configured to determine a volume of instillation fluid that has been delivered to the wound, to operate the pneumatic pump and the valve to apply a negative pressure to the wound dressing apparatus to purge a first portion of the instillation fluid, and to operate the pneumatic pump and the valve during a purge operation to deliver a volume of air through the wound dressing apparatus that is approximately equal to or greater than the volume of instillation fluid to purge a second portion of the instillation fluid from the wound dressing apparatus. | 2022-09-15 |
20220288297 | WOUND DRESSING WITH MULTIPLE TREATMENT ZONES - A customizable wound treatment system for treating multiple zones of a wound includes a dressing configured for use with a first zone and a second zone of a wound that includes a first foam layer placed over the first zone, a second foam layer placed over the second zone, a first drape layer disposed over the first foam layer and beneath the second foam layer, and a second drape layer disposed over the second foam layer. The customizable wound treatment system includes a negative pressure source pneumatically coupled to the first foam layer and the second foam layer and operable to create a negative pressure at the first zone and the second zone and a fluid instillation pump fluidly coupled to the first foam layer and configured to instill a treatment fluid to the first zone. | 2022-09-15 |
20220288298 | SYSTEMS AND METHODS FOR MONITORING ESSENTIAL PERFORMANCE OF WOUND THERAPY - A negative pressure wound therapy system can include a reduced pressure wound therapy device and a wound therapy monitoring device configured to emit an indication when it detects that at least one parameter associated with the provision of negative pressure wound therapy is outside an operational range. The wound therapy monitoring device can operate in a low power mode in which the at least one parameter is periodically monitored. The reduced pressure wound therapy device can be configured to detect the indication and selectively generate an alarm. In some cases, the wound therapy monitoring device can be disposed in a wound or in a fluidic connector connecting the reduced pressure wound therapy device to the wound. | 2022-09-15 |
20220288299 | PEN NEEDLE MAGAZINE - A pen needle magazine ( | 2022-09-15 |
20220288300 | ADAPTABLE ASYMMETRIC MEDICAMENT COST COMPONENT IN A CONTROL SYSTEM FOR MEDICAMENT DELIVERY - The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage). | 2022-09-15 |
20220288301 | LIQUID MEDICINE INJECTION DEVICE - A liquid medicine injection device includes: a liquid medicine storage unit including a cylinder including a space configured to store liquid medicine therein and a discharge hole connected to the space, and a piston arranged inside the cylinder and moving toward the discharge hole depending on discharge of the liquid medicine; a first electrode on an outer surface of the cylinder; a second electrode on the outer surface of the cylinder, the second electrode facing the first electrode with the piston therebetween; and a circuit unit including a substrate electrically connected to the first electrode and the second electrode. | 2022-09-15 |
20220288302 | PUMPING MECHANISM WITH WIRE-PULLED PLUNGER - Disclosed herein are devices and methods for causing the linear translation of a plunger through a reservoir containing a fluid. A flexible member, for example, a wire or a ribbon, is coupled to the plunger and extends through a wall of the reservoir toward which the plunger is being linearly translated. A pulling force on the flexible member caused by a drive mechanism causes the plunger to linearly translate toward the end wall of the reservoir, thereby forcing any fluid contained in the reservoir out of the reservoir through a fluid port. | 2022-09-15 |
20220288303 | Diabetes Overlay Patch Shield - An article of manufacture for providing a diabetes overlay patch shield is disclosed. The diabetes overlay patch shield includes a vertical supporting wall structure having an outer surface, a top edge and a bottom edge, the vertical supporting wall structure surrounds a cavity configures to match a shape of an on-body device, a set of supporting fingers coupled to the bottom edge of the vertical supporting wall structure radiating outward from the outer surface, the set of supporting fingers having a bottom surface, and adhesive attached to the bottom surface of the set of supporting fingers to hold the diabetes overlay patch shield. An overlay patch sized to cover the entire the diabetes overlay patch shield is attached over the diabetes overlay patch shield once in place. | 2022-09-15 |
20220288304 | DRIVE MECHANISMS FOR POSITIVE DISPLACEMENT PUMPS - A novel embodiment of a pump system, for example, of the type that would be used in a wearable drug delivery system, comprises, in a preferred embodiment, a reservoir, a plunger, disposed within the reservoir and driven by a scissor mechanism connected to a drive mechanism through a linkage, such that a force imparted by the drive mechanism in causes the scissor mechanism to expand thereby causing the plunger move within the reservoir to force a liquid drug contained within the reservoir through a fluid port to a patient. | 2022-09-15 |
20220288305 | PRESSURE RELIEF VALVE FOR DRUG DELIVERY DEVICE - A drug delivery device includes a housing releasably coupled with a patient, a pressure chamber disposed in the housing and including a vent, a container at least partially disposed in the pressure chamber for storing a drug connectable in fluid communication with a fluid conduit, an activation mechanism, and a relief mechanism. The activation mechanism releases a pressurized drive fluid into the pressure chamber for expelling the drug from the container into the fluid conduit. The relief mechanism is operably coupled to the fluid conduit and is adapted to open the vent to release the drive fluid from the pressure chamber in response to a predetermined condition. | 2022-09-15 |
20220288306 | APPARATUS FOR SUBRETINAL ADMINISTRATION OF THERAPEUTIC AGENT VIA A CURVED NEEDLE - An apparatus includes a body, a cannula, and a needle. The cannula is flexible and extends distally from the body. The needle is slidably disposed in the cannula. The needle includes a sharp distal tip and a curved portion. The needle is configured to translate relative to the cannula between a proximal position and a distal position. The distal tip is configured to be positioned inside the cannula when the needle is in the proximal position. The distal tip is configured to be positioned outside the cannula when the needle is in the distal position. The needle is resiliently biased to extend along a curve through the curved portion. | 2022-09-15 |
20220288307 | Needle Guard - A method of making a needle guard includes providing a mold having a portion defining a volume, the volume being a hollow cylinder with non-uniform walls with a pair of slots therein, the slots being open at one end and closed at the other end, the pair of slots having a major portion of constant width. The walls are thicker at the other end than at the one end. The method includes filling the volume with polymer and releasing a molded part from said mold and cooling a molded part resulting from the filling and releasing such that temperature that the widths of the pair of slots is non-uniform after cooling. The needle guard has upper and lower jaws defining a channel and coming together at a hinge. A winged needle can be inserted between the jaws, with the wings of the winged needle passing through slots between the jaws. | 2022-09-15 |
20220288308 | Blood Infusion System for Controlling Concentration of Calcium in Blood Infusate - An infusion pump system is operable to deliver blood to a patient from a first fluid reservoir via a first pump while mixing in a calcium-containing solution from a second fluid reservoir via a second pump. The controller precisely controls the amount of calcium-containing solution that is administered to the patient to be mixed with the blood infusate in the patient's bloodstream according to a preset blood-calcium ratio, thereby preventing citrate intoxication during large blood transfusions. | 2022-09-15 |
20220288309 | AMBULATORY MEDICAL DEVICE DATA ACCESS MANAGEMENT VIA WIRELESS WIDE AREA NETWORK - Systems and methods presented herein relate to managing ambulatory medical device data access. A computing system of a networked computing environment can establish a direct end-to-end data connection to an ambulatory medical device via a wireless wide area network. A public key of the computing system may be transmitted to the ambulatory medical device permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The computing system may receive, via the direct end-to-end data connection, encrypted data from the ambulatory medical device, and upon decrypting the data can generate a therapy report based at least in part on the therapy data. This therapy report may include time-series therapy data relating to the therapy delivered by the ambulatory medical device over a particular time period. The computing system can restrict access to the therapy report to authorized users. | 2022-09-15 |
20220288310 | Pharmacotherapy of Neurosystem Dysfunctions - Release of a neurological drug in a targeted region of a subject's brain by a drug delivery system (DDS) is intentionally caused by the subject watching or interacting with an audio/video-based task on an electronic display. The DDS is calibrated to release the neurological drug based on a particular pH, lactate level, blood flow, temperature, magnetic field, specific molecules released by brain cells, or other physiological factors within the target region. The interactive task produces the physiological factors in the brain in specific areas of pathology for which the drug is prescribed, and limits drug delivery at areas unaffected by illness where it could disrupt normal function, causing problematic side effects and preventing dose levels optimal for target impact. Feedback from the interactive task and associated cognitive probes also can adapt the interactive task or suggest new pharmacologic agents as the degree or primary focus of brain pathology changes during the course of treatment. | 2022-09-15 |
20220288311 | ADAPTIVE UPDATE OF AUTOMATIC INSULIN DELIVERY (AID) CONTROL PARAMETERS - Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles. | 2022-09-15 |
20220288312 | SYSTEMS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS IN PARKINSON DISEASE SUBJECTS - Systems and methods are provided for treating a condition associated with a Parkinson's disease (PD) subject, for example for treating or ameliorating motor and/or nonmotor symptoms or disorders in Parkinson's disease patients. An example system may include a sleep sensing circuitry and a drug dispensing device. The sleep sensing circuitry may be used to detect a sleep pattern of a PD patient, and the drug dispensing device may be used to continuously deliver a therapeutically effective compound to the PD patient based on the sleep pattern. Operational parameters of the drug delivery device (e.g., drug delivery flow rate and drug delivery timing) may be pre-programmed prior to bedtime and/or be adjusted in real time, for example during sleep, based on the detected sleep pattern to treat a condition associated with the PD subject, for example to optimize sleep, improve sleep quality, ameliorate non-motor disorders in the treated PD patient, etc. | 2022-09-15 |
20220288313 | REGULATION OF INSULIN ON BOARD - Disclosed herein are techniques related to regulation of insulin on board. In some examples, the techniques may involve obtaining a glucose measurement value generated from a sensing arrangement. The techniques may also involve determining that the glucose measurement value is a valid glucose measurement value. Furthermore, the techniques may involve maintaining a threshold amount of insulin on board (IOB) based on regulating insulin delivery. Maintaining the threshold amount of IOB may be performed responsive to the valid glucose measurement value being less than a threshold glucose value. | 2022-09-15 |
20220288314 | WEARABLE MEDICATION DELIVERY DEVICE - Systems and methods for delivering a medication to a person experiencing an emergency medical event without requiring intervention or action on the part of the person. A device encases a reservoir of medication and a delivery mechanism. Sensors in the housing sense a physical attribute of the person and circuitry monitors information collected by the sensors to determine if the person is experiencing a severe medical condition or event based on the information. An input device on or in the housing, such as a button, may be used or activated by the person if the detected condition or event is a false positive to cancel further action. If the system does not include the button or if the user does not press it in time, the system activates the delivery device and injects the medication into the person. | 2022-09-15 |
20220288315 | DRUG DELIVERY DEVICE HAVING REMOVABLE CAP - A drug delivery device including a housing, a drug storage container, and a removable cap is provided. The removable cap may be configured to be removably coupled with the housing such that the removable cap has a storage position where the removable cap is coupled with the housing and at least partially covering an opening in the housing and a removed position where the removable cap is not coupled with the housing. The removable cap may include an outer portion, an inner portion, and a gap separating at least a portion of the inner portion and at least a portion of the outer portion such that the at least a portion of the outer portion is allowed to bend with respect to the at least a portion of the inner portion if the at least a portion of the outer portion is subjected to an external force. Additionally or alternatively, the removable cap may be configured such that an external force applied to the removable cap induces at least one bending moment in a proximal end and/or a distal end of the removable cap. | 2022-09-15 |
20220288316 | AUTO INJECTOR WITH CHARGER SAFETY - An auto injector is disclosed comprising: a housing, a cartridge receiver, and an ejector member. The cartridge receiver is configured to receive a cartridge containing the medicament. The auto injector further comprises a blocking member coupled to an ejector member. The blocking member is configured to move between a blocking position wherein a connector opening is blocked and a non-blocking position wherein the connector opening is not blocked. | 2022-09-15 |
20220288317 | DEVICE FOR AUTOMATICALLY OPERATING STAMP-TYPE FLUID INJECTOR HAVING FINE NEEDLES FOR HAIR LOSS CARE AND TREATMENT - Proposed is a device for automatically operating a stamp-type fluid injector having fine needles for hair loss care and treatment. A hole is formed at the center of a cover coupled to the lower portion of an outer case such that an outer cap is moved up and down in the hole by a motor. An inner cap elastically operated by a spring is disposed under the outer cap, a flexible cap is disposed in the inner cap, and a fluid injector is simply inserted into and separated out of the flexible cap through the hole of the cover. Accordingly, it is possible to uniformly and continuously tap the scalp by automatically moving up and down a fluid injector by operating the motor. Further, a fluid injector can be more conveniently used, as compared with when it is manually used. | 2022-09-15 |